Tesamorelin

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) modified with a trans-3-hexenoic acid group at the N-terminus. This modification protects against enzymatic degradation while maintaining full biological activity at the GHRH receptor, resulting in enhanced pharmacokinetic properties compared to native GHRH.

The compound stimulates GH secretion through binding and activation of pituitary GHRH receptors, producing physiological pulsatile GH release. Unlike exogenous GH administration, tesamorelin preserves the negative feedback mechanisms that regulate endogenous GH secretion.

Clinical research has focused particularly on HIV-associated lipodystrophy, where tesamorelin has demonstrated significant reductions in visceral adipose tissue. Studies show approximately 15-18% reduction in trunk fat while preserving subcutaneous fat depots, along with improvements in lipid profiles and patient-reported body image outcomes.

Ongoing research explores tesamorelin's potential in non-alcoholic fatty liver disease (NAFLD), where GH's lipolytic and hepatoprotective effects may provide therapeutic benefit. Studies have shown reductions in liver fat content and improvements in hepatic fibrosis markers, positioning tesamorelin as a candidate for metabolic liver disease intervention.